Virtu Financial LLC trimmed its holdings in shares of AnaptysBio (NASDAQ:ANAB) by 65.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,923 shares of the biotechnology company’s stock after selling 5,584 shares during the quarter. Virtu Financial LLC’s holdings in AnaptysBio were worth $294,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also modified their holdings of the company. New York State Common Retirement Fund grew its holdings in AnaptysBio by 21.4% during the third quarter. New York State Common Retirement Fund now owns 8,500 shares of the biotechnology company’s stock valued at $297,000 after purchasing an additional 1,500 shares during the period. Teachers Advisors LLC grew its holdings in AnaptysBio by 23.4% during the second quarter. Teachers Advisors LLC now owns 9,520 shares of the biotechnology company’s stock valued at $228,000 after purchasing an additional 1,807 shares during the period. Alps Advisors Inc. grew its holdings in AnaptysBio by 10.0% during the third quarter. Alps Advisors Inc. now owns 20,034 shares of the biotechnology company’s stock valued at $700,000 after purchasing an additional 1,824 shares during the period. Legal & General Group Plc grew its holdings in AnaptysBio by 160.8% during the third quarter. Legal & General Group Plc now owns 3,164 shares of the biotechnology company’s stock valued at $110,000 after purchasing an additional 1,951 shares during the period. Finally, Raymond James Financial Services Advisors Inc. bought a new position in AnaptysBio during the fourth quarter valued at $252,000. 99.25% of the stock is owned by institutional investors.
Several brokerages have weighed in on ANAB. Wedbush reissued an “outperform” rating and set a $142.00 price objective on shares of AnaptysBio in a report on Tuesday, February 20th. Stifel Nicolaus set a $152.00 price target on AnaptysBio and gave the stock a “buy” rating in a report on Monday, March 26th. Jefferies Group raised their price target on AnaptysBio from $6.59 to $145.00 and gave the stock a “buy” rating in a report on Monday, February 19th. SunTrust Banks raised their price target on AnaptysBio from $115.00 to $162.00 and gave the stock a “buy” rating in a report on Thursday, February 15th. Finally, ValuEngine raised AnaptysBio from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. AnaptysBio has a consensus rating of “Buy” and an average target price of $131.44.
NASDAQ:ANAB opened at $85.51 on Friday. The firm has a market cap of $2,246.47, a P/E ratio of -56.26 and a beta of 3.26. AnaptysBio has a 52-week low of $18.15 and a 52-week high of $134.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 17.93 and a quick ratio of 17.93.
AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Monday, March 5th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.12. The business had revenue of $3.00 million for the quarter, compared to the consensus estimate of $0.89 million. AnaptysBio’s revenue for the quarter was up 9.1% compared to the same quarter last year. equities research analysts anticipate that AnaptysBio will post -2.3 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “AnaptysBio (NASDAQ:ANAB) Shares Sold by Virtu Financial LLC” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.dispatchtribunal.com/2018/04/07/virtu-financial-llc-reduces-stake-in-anaptysbio-inc-anab.html.
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.